Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback